Atl1102 a Blockbuster drug .

Atl1102 to tackle the inflammation market worth $187 billion per annum..
Corticosteroids have been used for over 60 years and clinicians use it because it provides safety and efficacy..However Clinicians are more cautious using Corticosteroids now because they are not approved ( off label ) use..for many indications...Litigation risk.

There is no trial to prove Efficacy in reducing Inflammation ...but Clinicians will look at data proving Efficacy, safety and tolerability..

Atl1102 has already proved this with MS and DMD.
and soon the DMD trial in Europe 2b ..( steroids are not approved in Europe for use for DMD)However Atl 1102 will be used in combination with steroids in this trial....
Also in my opinion more animal studies in Melbourne will generate more data..

Heres the thing $$
Physicians can use Atl1102 in combination with Steroids before Atl1102 can be approved..for inflammation..(off label)
So early $$ income for ANP.